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Abstract
Diverse glycans on proteins help impact cell and organism physiology along with drug activity. 
Since many protein-based biotherapeutics are glycosylated and these glycans have biological 
activity, there is a desire to engineer glycosylation for recombinant protein-based biotherapeutics. 
Engineered glycosylation can impact the recombinant protein efficacy and also influence many 
cell pathways by first changing glycan-protein interactions and consequently modulating disease 
physiologies. However, its complexity is enormous. Due to recent advances in glycoengineering, 
modulating protein-glycan interactions become more amenable to therapeutic approaches. Here, 
we discuss how engineered glycans contribute to therapeutic monoclonal antibodies (mAbs) in the 
treatment of cancers, how these glycoengineered therapeutic mAbs affect the transformed 
phenotypes and downstream cell pathways, and how systems biology can help in the next 
generation mAb glycoengineering process by aiding in data analysis and guiding engineering 
efforts to tailor mAb glycan and ultimately drug efficacy, safety and affordability.
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Introduction
Monoclonal antibodies (mAbs) are the major category of glycoprotein-based therapeutic 
drugs, approved by the US Food and Drug Administration (FDA) [1]. Furthermore, they 
have attained considerable success in many therapies, including cancer, over the past three 
decades [2]. Despite remarkable advances in contemporary biopharmaceutical technologies, 
many challenges remain in efficiently manufacturing effective and affordable antibody-based 
drugs. Since glycosylation essentially impacts the therapeutic efficacies of mAbs [3], it is 
desirable to control glycoforms on therapeutic mAbs for the next generation mAb 
development. With fast growing innovative engineering and cutting-edge technologies, 
glycoengineering provides a promising method to tune the activities of therapeutic mAbs 
[4,5]. An effective glycoengineered mAb usually modulates specific interactions between 
designed glycans and target proteins, thereby impacting the activity of downstream pathways 
that control cancer physiology. Conversely, a wrong glycan can induce unwanted side effects 
and even adverse immunogenic response [6]. For example, some colorectal cancer patients 
develop hypersensitivity to the FDA approved mAb cetuximab [7].
Several intriguing and unsolved questions in mAb glycoengineering include the following. 
Which glycan structures will provide the optimal mAb? How can we efficiently and reliably 
engineer a consistent glycoform on mAbs? Challenges in answering these questions stem 
from our limited understanding regarding the intricate relationships between glycans, 
proteins, and host cell physiologies. Furthermore, even when desired glycoforms are known, 
it has been difficult to unravel all of the factors that influence glycosylation and to control 
the complex system.0020Systems biology provides a powerful toolbox for integrating 
heterogeneous omics data and for deciphering the mechanisms and interactions between 
molecules and pathways, using network analysis, mathematical modeling, and simulation 
[8,9]. An abundance of omics technologies have been developed to aid in studying 
glycoengineering and expression systems (e.g., [10]), but the application of omics data and 
systems biology in glycoengineering is still in its infancy. Here we review the state-of-art 
knowledge of glycan-protein interactions in the context of FDA-approved therapeutic mAbs 
and then summarize several innovative technologies that can help control the glycoforms on 
mAbs. Finally, systems biology-based glycoengineering approaches are explored with an 
emphasis on how systems biology can be used to advance anti-tumor mAb development 
toward a predictable glycoengineering era.
Glycan-protein interaction, therapeutic antibody, and cancer physiology
Glycosylation helps to modulate interactions between mAbs and antigens or Fcγ receptors 
(Figure 1A), and impact the efficacy and safety of a biotherapeutic drug. The glycan-protein 
interactions of FDA-approved therapeutic mAbs in various cancer settings and their 
subsequent effects reported in the literature are summarized in Table 1.
Fab-antigen interaction
Fab glycans have several roles in modulating interactions with receptors and 
glycoengineering can help reduce negative interactions leading to immunogenicity. Early 
research demonstrated that engineering N-linked oligosaccharides on the Fab region can 
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enhance the antigen-binding affinity of mAbs [11]. However, a comprehensive 
understanding of the glycans on Fab region is still lacking. One example of their role is the 
allergenic responses to therapeutic antibody cetuximab [7]. It was produced by murine 
myeloma cells (SP2/0), which adds an additional α1,3-galactose (the α-Gal epitope) on the 
N-linked oligosaccharide at Asn88 of the Fab region (Figure 1A). Unfortunately, the human 
IgE recognizes the non-human α-Gal epitope and leads to downstream immune responses, 
such as hypersensitivity reactions (anaphylaxis) after drug treatments. Therefore, extra 
efforts must be made to glycoengineer the drug to reduce α-Gal content and solve the 
immunogenicity problem (e.g., [12]). Moreover, the Fab-antigen binding affinity could be 
affected by targeting receptors. Recent mutagenesis studies showed that the potential 
glycosylation sites (Asn16, Ans25, Asn41, and Asn83) on Programmed death 1 (PD1) could 
impact antigen-binding affinity (e.g., nivolumab and pembrolizumab) by influencing its 
local structure [13]. Physiologically, PD1 is an inhibitory receptor that suppresses T cell 
responses to avoiding auto-immunity. Indeed, many factors can affect Fab-antigen binding in 
cancer treatment, and glycoengineering can be applied in mAb design either to optimize 
Fab-antigen binding affinity or to eliminate immunogenicity problem.
Beyond immunogenicity, Fab-binding can target cancer by modulating glycan-protein 
interactions. This occurs by either directly targeting glycans (Fab-glycan interaction) or 
indirectly modulating downstream protein-glycan interactions to treat cancer. At least four 
types of glycan-protein interactions involving the Fab have been explored. First, the Fab can 
interact with a target glycan, such as seen with Alemtuzumab which directly targets a 
glycosylphosphatidylinositol (GPI) anchor on the CAMPATH-1 (CD52) antigen to treat 
chronic myeloid leukemia. CD52 plays a dominant role in mediating cell depletion via 
apoptosis [14]. Second, the Fab can target siglec-sialic acid interactions of inhibitory siglecs 
(e.g., CD22) that normally prevent B-cell over-stimulation by inhibiting B-cell receptor 
signaling [15]. For example, the anti-CD22 antibody (epratuzumab) targets siglec-sialic acid 
interactions between B cells with endothelial cells, leading to downstream B-cell receptor 
signaling suppression [16]. Third, the Fab can interfere with angiogenesis by blocking 
interactions between glycans and VEGF, a key inducer for several downstream signaling 
pathways (e.g., MAPK and PI3K/AKT [17]) that lead to vascular and stromal cell ablation 
[18]. Bevacizumab binds VEGF to interrupt interactions between VEGF and heparin sulfate 
proteoglycans (HSPGs), leading to VEGF-VEGFR interaction blockade [19]. Fourth, mAbs 
can modulate Gal1-N-linked glycan interactions. Specifically, anti-VEGF refractory tumors 
can secrete excess Galectin-1 (Gal1). This enables tumor immune escape and metastasis by 
interacting with the β1,6-GlcNAc branching N-glycans on the endothelial cell receptors 
[20]. Anti-Gal1 antibodies can block the interaction between Gal1 and the N-glycan on 
VEGFR, leading to angiogenesis inhibition. While some mAbs might not require a 
glycosylation on the Fab-antigen binding site, to successfully interrupt downstream glycan-
protein interactions, engineering glycosylation can improve their pharmacological properties 
(e.g., stability and effector functions) for maintaining optimal efficacy (see discussion 
below).
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Fc-FcγR interaction
Fc binding with the Fcγ receptor (FcγR) on immune cells is crucial to mAb efficacy in 
governing downstream immunological responses of complement-dependent cytotoxicity 
(CDC) [21] and antibody-dependent cellular cytotoxicity (ADCC) [22] activities, which are 
immune mechanisms for killing target cells. In essence, the interaction between Fc and 
FcγR is a glycan-glycan interaction that is significantly affected by Fc-glycosylation (at 
Asn297). Indeed, mAbs with aglycosylated Fc regions lose effector functions, and mAbs 
with glycosylated Fc can activate downstream effector mechanisms. However, different 
engineered glycoforms significantly alter the efficacies of effector functions; for example, 
removal of the α1,6-linked core fucose from IgG-Fc glycans results in better effector 
functions compared to the IgG with fucosylated Fc glycans [23]. The N-glycans attached to 
the FcγRIIIa mediate the interaction with nonfucosylated IgG1-Fc, thereby stabilizing the 
Fc-FcγRIIIa complex, while fucosylation of the Fc N-glycans otherwise inhibits the 
interaction due to the steric hindrance. NMR analysis shows that defucosylation facilitates 
the active conformation of the Fc Tyr296 and the formation of a high-affinity complex; 
however, presence of fucose inhibits complex formation by reducing the flexibility of 
Tyr296. Other modifications to glycans further impact function. For example., bi-antennary 
N-glycans that are terminated with alpha-2,6-linked sialic acids is an optimal structure to 
enhance effector functions by strengthening interactions with the FcγRIIIa [24]. 
Intriguingly, effector functions are highly correlated with structural stability [25,26]. 
Glycosylated mAbs exhibit better structural stability and aglycosylated mAbs tend to unfold 
[27]. Indeed, a recent study indicated that an Fc Nglycan substantially stabilized the 
conformation of the Fc C’E loop by interacting with self-protein. Interestingly, the C’E loop 
stability is correlated with the Fc-binding affinity [28]. Moreover, an Fc with bisecting or 
high galactosylation N-glycans may open up the horseshoe-shaped conformation of the Fc 
fragment, which is favored by Fc-FcγR interaction, resulting in the enhanced effector 
functions [29]. In addition, different glycoforms also impact the pharmacokinetic behavior 
of mAbs [30]. Indeed, glycosylated mAbs can significantly increase their serum half-life, 
due to the prevention of proteolytic degradation [31]. Indeed, conformational changes of 
aglycosylated mAbs increase protease accessibility to the hinge region [32]. Notably, 
terminal sugars affect proteolytic resistance; glycoengineered mAb terminated with GlcNAc 
(G0 glycoforms) showed at least two times greater resistance to papain digestion than those 
terminated with sialic acid (G2S2 glycoform) and beta-galactose (G2 glycoform) [33].
Two glycoengineered mAbs have been approved by the FDA — mogamulizumab and 
obinutuzumab. Mogamulizumab targets CC chemokine receptor 4 (CCR4) to inhibit CCR4-
mediated signal transduction pathways for T-cell leukemia/lymphoma treatment [34]. The 
antitumor activity strongly relies on ADCC, which is enhanced by glycoengineered 
afucosylated-Fc [35]. Obinutuzumab targets CD20 to treat chronic lymphocytic leukemia by 
directly inducing tumor cell apoptosis. Obinutuzumab demonstrated superior antitumor 
activity than rituximab, a leading FDA-approved CD20-targeting mAb. The superiority of 
obinutuzumab comes from the enhanced ADCC by glycoengineering afucosylated N-
glycans with bisecting GlcNAc [36]. Inspired by these successful examples, more than 20 
glycoengineered mAbs are currently in clinical trials.
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Remarkably, the structure of glycans and their locations are the two most prominent 
properties governing the interaction between mAb and receptor, three generally desired 
properties of glycosylation on mAbs are summarized. First, removal of the N-glycan on Fab 
(Asn88) could avoid immunogenicity. Second, modulation of N-glycans on the Fc (Asn297) 
can enhance structural stability and Fc binding affinity. Third, three structures for the N-
glycan on Fc (Asn297) have shown to enhance effector functions (ADCC/CDC): the bi-
antennary N-glycans terminated with two alpha-2,6-linked sialic acids (ADCC) [24], the 
afucosylated Fc (ADCC) [23], and the high galactosylated Fc (CDC) [42]. These properties 
have been considered extensively while glycoengineering mAbs, but it is possible that many 
more desirable structures and locations on mAbs remain undiscovered.
Glycoengineering to control glycoforms on therapeutic proteins
While there is a vast diversity of glycans in mammalian cells, far fewer are commonly on 
mAbs (Figure 1B). Novel technologies and knowledge allow us to modify the glycan for 
more effective mAbs for cancer treatments. Glycoengineered mAbs can enhance therapeutic 
efficacy (antigen binding affinity and effector functions) and safety (immunogenicity). They 
also influence other properties (e.g., pharmacokinetics (PK) and pharmacodynamics (PD)) 
on biotherapeutics, which has been covered elsewhere recently (see [37–39]).
There are three major considerations when glycoengineering mAbs for cancer therapy. First, 
modified glycans should minimize immunogenicity. Most protein expression systems are 
nonhuman, and if the non-human sugars and linkages are added to the mAbs (e.g., fucose or 
xylose in plants [40]), severe adverse drug reactions can occur (e.g., "Cytokine Storm" of 
TGN142 [41] and anaphylaxis of cetuximab [7]). Indeed, several glycoforms from 
heterologous expression systems (see Figure 1B (ii)) have been identified to be 
immunogenic to human. Thus, incompatible expression systems need to be humanized by 
knocking out relevant transferases (Figure 1C (i)), or human-compatible expression systems 
(e.g., Chinese hamster ovary cells) must be selected to create safe and bioactive glycoforms.
A second consideration for glycoengineering in cancer therapeutics is the need to enhance 
effector functions, such as ADCC and CDC. Many studies have reported that N-linked 
glycans at Asn297 in the Fc region are crucial to ADCC. Glycoengineering by depleting 
fucosylation or increasing N-glycan branching (e.g. by over-expressing the GnTIII gene) can 
improve ADCC. These glycoforms increase binding affinity to Fc-FcγRIIIa [25]. The CDC 
effector function can also be modulated through glycoengineering. Specifically, high 
galactosylation can improve effector function of CDC, and this can be achieved by process 
engineering of adding uridine, manganese chloride, and galactose in media [42]. The 
increased galactosylation can improve the binding affinity between the mAb and 
complement (C1q) [43].
A third consideration is that glycoengineering can enhance antigen-binding affinity. mAb 
affinity has been widely studied, and efforts use tools like phage-display libraries, combined 
with point mutations, to engineer the protein for improving antigen-binding affinity [44]. 
However, glycoengineering mAbs by introducing more N-glycosylation sites using protein 
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engineering can improve antigen-binding affinity. For example, adding an N-glycan at 
Asn58 on Fab region can increase antigen-binding affinity by 50 fold [11].
Systems biology for predictive and rational glycoengineering of mAbs
In the past decade, considerable efforts have aimed to control glycosylation through media 
optimization, chemical treatments, or genetic changes (e.g., [45]). Despite many successful 
examples, it is still challenging to obtain desired quality and quantity of mAbs. However, 
omics technologies and systems biology modeling promise to aid in the glycoengineering of 
improved anti-tumor mAbs [10] (Figure 2). Indeed, systems biology provides platforms to 
integrate omics data with a holistic perspective, thereby guiding glycoengineering while 
accounting for competing pathways and processes [46]. Moreover, computational models in 
systems biology can be used for predicting knock-in or knockout strategies to obtain desired 
glycoforms [47].
Systems biology holds great promise in advancing at least three glycoengineering processes. 
First, it can be used for reliable cell line development. Cell line development is often a 
bottleneck step in protein-based drug manufacturing (usually taking more than a year). 
Many cellular processes must be considered during cell line development, since they 
influence protein quality and glycosylation. These include metabolism, protein secretion, 
and cell growth/apoptosis [48]. Computational models can be developed to understand how 
to control these processes in expression systems, as we can predict growth characteristics 
and production capabilities of mAbs [49,50]. Second, with increased understanding of the 
molecular pathways influencing mAb production, models can be used for predictable 
glycoengineering. The complexity of glycosylation greatly hampers the glycoengineering 
process. Computational models have been developed that enables us to predict glycoforms 
under different glycoengineering strategies [47,51]. The third area where systems biology 
can aid in glycoengineering is for its use in assessing the physiological effects of 
glycoengineering. Some glycoengineering designs have proven toxic to host cell lines; for 
example, the OCH1 deletion [52] and double knockouts of PMT-family genes [53] in yeast 
were shown to significantly reduce host-cell fitness. However, there has not been a 
systematic study concerning how glycoengineering affects host cells and their protein 
secretion system. In the future, we can combine several omics data (e.g., transcriptomics 
[54,55] and glycomics [56]) and relevant phenotypes (e.g., [57]) to analyze them with 
systems biology approaches. These results can provide insights into how key metabolic and 
signaling pathways are modulated by alterations in glycosylation [58]. We are also hopeful 
that future research should be pursued in developing reliable prediction models for 
predicting outcomes of glycosylation alterations on mAbs. Ultimately, a clear blueprint of 
what glycosylation to be engineered on a mAb with desire properties of low cost, safety and 
effectiveness will be revealed.
Conclusions
While therapeutic effects of mAbs are profoundly influenced by how the glycans impact 
cancer physiology, the detailed mechanistic relationships are largely unknown. By analyzing 
the FDA-approved mAbs in oncology indications, deeper insights will be obtained into how 
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glycosylation and glycan-protein interactions impact on cancer physiology. In the future, 
systems biology technologies will aid in glycoengineering as it will allow us to better control 
and engineer glycans at the system level, thus, facilitating the development of novel 
therapeutic mAbs with increased efficacy, safety, and affordability.
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Highlights
* Glycan-protein interactions modulate tumor cell killing.
* Different glycans can significantly alter the glycan-protein interactions.
* Glycan structure and location on mAb are essential properties need careful 
control.
* Glycoengineering can modify glycans on therapeutic mAbs with desired 
glycoforms.
* Systems biology can advance mAb glycoengineering toward a rational 
design era.
Chiang et al. Page 11
Curr Opin Struct Biol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Therapeutic mAb structure, glycoforms, and glycoengineering strategies for generating 
desired glycoforms
(A) The structure of an IgG with interaction-partner binding regions and N-linked 
glycosylation sites (highlighted in blue triangles) are annotated. (B) The dominant N-linked 
glycans on mAbs can vary depending on the host and product. However, (i) common glycans 
on therapeutic mAbs have been measured. (ii) MAbs expressed in heterologous expression 
systems introduce non-human compatible sugars and linkages, leading to immunogenicity 
and low serum half-life. (iii) Glycoengineering aims to make mAbs with N-glycans that are 
human compatible and exhibit enhanced mAb efficacy and safety. (C) Many 
glycoengineering efforts aim to enhance the drugs and achieve any of the three effects (i-iii) 
by modifying glycans on mAbs. NANA: N-glycolylneuraminic acid (hyper-sialylation). 
Data of (B) in this figure was adapted from [34].
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Figure 2. Omics data and systems biology provide novel tools for rational glycoengineering of 
therapeutic mAbs and to assess the impact of glycoengineered mAbs on cancer
(A) Omics data can be acquired to identify how to glycoengineer mAb production cells. (B) 
Computational models of the pathways influencing glycosylation and protein production can 
serve as a platform for interpreting omics data and (C) guiding the rational design of glycans 
on therapeutic mAbs. (D) The impact of engineered mAbs on cancer physiology can further 
be analyzed using systems biology techniques, especially assessing the glycan-protein 
interactions [9].
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Table 1
Cancer physiology impacted by the FDA approved therapeutic mAbs through glycan-protein interactions
Targeting
mechanism
Impacted
physiologies in
tumors
State-of-art knowledge of glycan-protein
interactions
Examples of FDA-
approved product
(Receptor; First 
approved indications)
Fab-antigen binding Tumor cell
proliferation 
reduced
(PI3K-AKT, 
MAPK);
Apoptosis of tumor
cells.
1 Additional N-glycan (e.g., Asn88 on 
cetuximab) can induce immunogenicity.
2 Alemtuzumab can directly interact with 
the glycan (GPI-anchor).
3 Epratuzumabcan can modulate glycan-
protein interactions between B-cell (siglec) 
and Endothelial-cells (sialic acid).
Cetuximab (EGFR; Head 
and neck, colorectal 
cancer)
Alemtuzumab (CD52; 
Chronic myeloid 
leukemia)
Epratuzumab (CD22; 
Acute lymphocytic 
leukemia)
Angiogenesis
inhibited
1 Bevacizumab can block downstream 
VEGFHSPGs interactions.
2 Gal1-Endothelial cell interactions provide 
new opportunities for developing mAbs to 
inhibit tumor growth and metastasis.
Bevacizumab (VEGF; 
Colorectal cancer)
T cell activation and
tumor cell killed
Fab-antigen binding affinity is affected by N-
glycans on receptors (e.g., Asn16, Ans25, Asn41,
and Asn83 at PD1).
Pembrolizumab (PD1; 
Ipi-refractory melanoma)
Nivolumab (PD1; 
Metastatic melanoma)
Fc-FcγR binding Tumor cell killed by
immune cells
(ADCC/CDC)
1 Asn297 is crucial to the Fc-FcγR binding 
affinity and effector functions (ADCC/
CDC), which is correlated with structural 
stability.
2 Mogamulizumab is the first 
glycoengineered mAb with afucosylated-
Fc.
3 Obinutuzumab is glycoengineered with 
afucosylated with bisecting GlcNAc N-
glycans, and showing superior antitumor 
activity than nonglycoengineered 
rituximab.
Mogamulizumab (CCR4; 
T-cell leukemia/
lymphoma)
Rituximab (CD20; 
Chronic lymphocytic 
leukemia)
Obinutuzumab (CD20; 
Chronic lymphocytic
leukemia)
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